{"id":"NCT00399542","sponsor":"Sucampo Pharma Americas, LLC","briefTitle":"Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation","officialTitle":"Phase 3, 12-Week, Multicenter, Double-Blind, Randomized, Efficacy and Safety Study of Lubiprostone for the Treatment of Irritable Bowel Syndrome With Constipation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2006-07","completion":"2006-07","firstPosted":"2006-11-15","resultsPosted":"2008-10-31","lastUpdate":"2019-12-17"},"enrollment":581,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Irritable Bowel Syndrome","Constipation"],"interventions":[{"type":"DRUG","name":"Lubiprostone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[],"summary":"The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.","primaryOutcome":{"measure":"Overall Responder Status","timeFrame":"12 weeks","effectByArm":[{"arm":"Lubiprostone","deltaMin":12.1,"sd":null},{"arm":"Placebo","deltaMin":5.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.023"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2},"commonTop":["Nausea","Diarrhoea","Headache"]}}